{"id":16818,"date":"2024-12-05T00:51:42","date_gmt":"2024-12-04T16:51:42","guid":{"rendered":"https:\/\/flcube.com\/?p=16818"},"modified":"2024-12-05T00:51:45","modified_gmt":"2024-12-04T16:51:45","slug":"jiangsu-recbio-technology-secures-private-placement-with-yangtze-river-pharmaceutical-for-vaccine-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16818","title":{"rendered":"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development"},"content":{"rendered":"\n

China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179<\/a>) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector.<\/p>\n\n\n\n

Proceeds Allocation for Vaccine Research and Development<\/strong>
The proceeds from this private placement, amounting to RMB 800 million (USD 110 million), will be directed towards the research and development of herpes zoster vaccine products, a critical area in the field of infectious disease prevention. Additionally, the funds will serve as supplementary operating capital, ensuring the company’s ongoing financial stability and support for its vaccine development initiatives.<\/p>\n\n\n\n

Strategic Implications of the Transaction<\/strong>
This collaboration between Jiangsu Recbio Technology and Yangtze River Pharmaceutical underscores the commitment of both companies to advancing public health through the development of innovative vaccines. The investment not only strengthens Jiangsu Recbio’s financial position but also enhances its capacity to bring new vaccines to market, particularly for diseases like herpes zoster, which poses significant health challenges for many individuals.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through…<\/p>\n","protected":false},"author":1,"featured_media":16819,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[20,1292,1291],"class_list":["post-16818","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-hkg-2179","tag-recbio-technology"],"yoast_head":"\nJiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16818\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development\" \/>\n<meta property=\"og:description\" content=\"China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16818\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-04T16:51:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-04T16:51:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"810\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development\",\"datePublished\":\"2024-12-04T16:51:42+00:00\",\"dateModified\":\"2024-12-04T16:51:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818\"},\"wordCount\":195,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0512.png\",\"keywords\":[\"Finance\",\"HKG: 2179\",\"Recbio Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16818#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16818\",\"name\":\"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0512.png\",\"datePublished\":\"2024-12-04T16:51:42+00:00\",\"dateModified\":\"2024-12-04T16:51:45+00:00\",\"description\":\"China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16818\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0512.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0512.png\",\"width\":1080,\"height\":810,\"caption\":\"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16818#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development - Insight, China's Pharmaceutical Industry","description":"China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16818","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development","og_description":"China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector.","og_url":"https:\/\/flcube.com\/?p=16818","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-04T16:51:42+00:00","article_modified_time":"2024-12-04T16:51:45+00:00","og_image":[{"width":1080,"height":810,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16818#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16818"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development","datePublished":"2024-12-04T16:51:42+00:00","dateModified":"2024-12-04T16:51:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16818"},"wordCount":195,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=16818#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512.png","keywords":["Finance","HKG: 2179","Recbio Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16818#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16818","url":"https:\/\/flcube.com\/?p=16818","name":"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=16818#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=16818#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512.png","datePublished":"2024-12-04T16:51:42+00:00","dateModified":"2024-12-04T16:51:45+00:00","description":"China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through a private placement to compatriot firm Yangtze River Pharmaceutical (Group) Co., Ltd. This transaction positions Yangtze River Pharmaceutical as the largest shareholder of Jiangsu Recbio, marking a significant strategic investment in the biotechnology sector.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16818#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16818"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=16818#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512.png","width":1080,"height":810,"caption":"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16818#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16818"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16818\/revisions"}],"predecessor-version":[{"id":16820,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16818\/revisions\/16820"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/16819"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}